Rebiotix completes enrollment for phase 3 trial of C. diff microbiota therapy

Investigators have completed enrollment in a phase 3 trial set to investigate RBX2660, a therapy that uses the gut microbiota to treat Clostridioides difficile infection, according to a press release issued by Rebiotix, the manufacturer.The company said this is the first microbiota-based formulation to reach phase 3 in the United States and Canada.“Microbiota-based therapies have shown tremendous potential as an innovative, non-antibiotic therapy, starting with C. diff,” Rebiotix founder and CEO Lee Jones said in the press release. The completion of enrollment of this trial is aRead More

Share on facebook
Share on twitter
Share on linkedin